1.17
0.02 (1.74%)
| Previous Close | 1.15 |
| Open | 1.15 |
| Volume | 113,300 |
| Avg. Volume (3M) | 314,582 |
| Market Cap | 2,037,637 |
| Price / Sales | 100.88 |
| Price / Book | 36.17 |
| 52 Weeks Range | |
| Earnings Date | 10 Apr 2025 - 15 Apr 2025 |
| Operating Margin (TTM) | -20,588.95% |
| Diluted EPS (TTM) | -42.65 |
| Quarterly Revenue Growth (YOY) | 194.80% |
| Total Debt/Equity (MRQ) | 349.84% |
| Current Ratio (MRQ) | 0.340 |
| Operating Cash Flow (TTM) | -24.67 M |
| Levered Free Cash Flow (TTM) | -15.22 M |
| Return on Assets (TTM) | -117.74% |
| Return on Equity (TTM) | -388.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Eyenovia, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.50 |
|
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 23.71% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nations Financial Group Inc, /Ia/ /Adv | 31 Dec 2024 | 1,125 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |